MediSix Therapeutics develops proprietary T-cell therapies, utilizing their unique Protein Expression BLocker (PEBL) technology to enhance T-cell function for patients with T-cell malignancies. The company addresses the limitations of existing CAR T-cell therapies, aiming to improve treatment outcomes for complex and rare cancers and autoimmune diseases.
Funding
$62.9M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
LVOUTFounders
Product
Problem
Existing CAR T-cell therapies face challenges in treating T-cell malignancies due to the difficulty of targeting malignant T-cells without also harming healthy T-cells. This limitation hinders the effectiveness of CAR T-cell therapy for complex and rare cancers and autoimmune diseases.
Solution
MediSix Therapeutics is developing T-cell therapies using its proprietary Protein Expression BLocker (PEBL) technology to enhance T-cell function and overcome the challenges of treating T-cell malignancies. The PEBL technology allows for more precise targeting of malignant T-cells, improving treatment outcomes for patients with complex and rare cancers and autoimmune diseases. By leveraging this technology, MediSix aims to expand the applicability and efficacy of T-cell therapies.
Target Audience
The primary target audience includes patients with complex and rare T-cell malignancies and autoimmune diseases, as well as the healthcare providers who treat them.
Features
- Proprietary Protein Expression BLocker (PEBL) technology for precise targeting of malignant T-cells.
- Focus on improving and expanding T-cell function.
- Robust pipeline of research in T-cell therapies.
- Development of therapies for complex and rare T-cell malignancies and autoimmune diseases.